A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Summary

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.

Timeline

Start

2019-03-26

Primary completion

2021-04-05

Completion

2022-01-10

Publications

• Peyrin-Biroulet L, Seenan JP, Armuzzi A, Lazar A, Eldred A, Doan T, Polakow SB, Al Mahi N, Liu M, Nader A, Bhatnagar S, Schreiber S. Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial. Adv Ther. 2026 Jun;43(6):2611-2630. doi: 10.1007/s12325-026-03517-3. Epub 2026 Apr 1.

Drugs

Indications